Highest-materiality recent filing
VolitionRx issues 545,591 shares to Lind Global to satisfy $833,332 in debt payments
On June 17, 2026, issued 333,332 shares to Lind for $416,666 payment obligation.
VolitionRx prices $4.6M public offering of common stock and warrants
Offered 2,960,000 shares at $1.55 each plus half-warrant; gross proceeds ~$4.6M.
Breached minimum market capitalization covenant on $7.5M (2025) and $2.4M (2026) convertible notes to Lind.
Director Mickie Henshall not standing for re-election; board reduces to 7 directors
Mickie Henshall notified board she will not stand for re-election at the 2026 Annual Meeting.
VolitionRx Q1 2026 revenue $1.0M; $5M milestone potential from feline lymphoma test
Revenue of $1.0M in Q1 2026 vs $0.2M in Q1 2025; operating loss decreased 3% YoY.
VolitionRx completes 1-for-20 reverse stock split effective April 28, 2026
Stockholders approved reverse split at special meeting March 31, 2026; Board set ratio at 1:20.
NYSE American accepts VolitionRx compliance plan; shares continue trading until Aug 2027 review
Received non-compliance notice on Feb 6, 2026 for stockholders' equity deficiency (below $2M threshold).
VolitionRx board approves 1-for-20 reverse stock split effective April 28, 2026
Reverse stock split ratio set at 1-for-20, effective 12:01 a.m. ET on April 28, 2026.
VolitionRx shareholders approve share issuance to Lind Global and reverse stock split authorization
Proposal 1 (issuance >20% to Lind Global): 44.15M for, 14.10M against, 1.11M abstain, 21.15M broker non-votes approved.
VolitionRx FY2025 revenue up 40% to $1.7M; net loss down 14%
Full-year revenue $1.7M (+40% YoY); Q4 revenue growth 133% vs prior year.
VolitionRx issues 6.4M shares to Lind Global to satisfy $1.42M debt payments
Feb 17, 2026: issued 1,956,178 shares to Lind Global for $416,666 payment.
Received NYSE American notice on Feb 6, 2026 for failing $2M, $4M, $6M stockholders' equity thresholds due to sustained losses.
VolitionRx secures $2.0M funding from Lind Global with convertible note and warrants
Gross proceeds $2M; issues $2.4M senior secured convertible note and 7,000,350 warrants at $0.5714/share.
VolitionRx subsidiary CEO Dr. Butera to depart Jan 31, 2026; position eliminated
Volition Veterinary CEO Dr. Salvatore Thomas Butera given termination notice, effective Jan 31, 2026.
VolitionRx amends over-allotment terms; underwriter buys 1.19M shares and 1.73M warrants
Amendment permits separate exercise of over-allotment shares and warrants, not just combined.
VolitionRx Q3 revenue up 32% to $0.6M; signs deals with Werfen and Hologic
Revenue $0.6M (+32% YoY); net loss down 8% YoY; operating expenses down 10% YoY.
Amendment allows Over-Allotment Option to be exercised separately for shares and/or warrants, not combined.
VolitionRx over-allotment exercised: 1.19M shares & 1.73M warrants sold at $0.52/unit
Underwriter exercised over-allotment option for 1,194,000 shares and 1,732,500 warrants at $0.52 per unit.
VolitionRx raises $6M in underwritten offering; only $0.3M cash pre-offering
Gross proceeds $6.0M from 11.55M units at $0.52; net ~$5.4M after underwriting discounts and expenses.
VolitionRx Q2 2025 revenue ~$0.4M; net loss down 11% YoY; expects first human licensing deal
Q2 2025 revenue just over $0.4M; H1 2025 revenue up 15% YoY.
VolitionRx raises $1.21M in registered direct offering; insiders buy stock
156,250 shares sold to directors/officers at $0.64/share; 1,734,375 shares + warrants at $0.64/unit.
VolitionRx shareholders approve authorized share increase to 325M; all director nominees elected
Authorized common shares increased from 175M to 325M effective June 18, 2025, via Certificate of Second Amendment.
VolitionRx Q1 revenue $0.25M (+44% YoY); first commercial revenue from CE-marked Nu.Q NETs in Europe
Revenue of ~$0.25M in Q1 2025, up 44% from Q1 2024; first revenue from regulated CE-marked Nu.Q NETs automated product.
VolitionRx enters up to $7.5M at-the-market stock offering agreement with JonesTrading
New 'Capital on Demand' sales agreement with JonesTrading allows sale of up to $7.5M common stock via ATM.
VolitionRx files S-1 to re-register 35.9M warrant shares previously covered by S-3
Filed new S-1 registration statement to register 35,867,306 shares of common stock issuable upon exercise of previously issued warrants.
VolitionRx reports FY2024 revenue up 59% to $1.2M; cash at $3.3M
Revenue $1.2M in 2024, up 59% YoY; Nu.Q Vet revenue up 75%, Nu.Q Discover up 40%.
VolitionRx announces $2.3M registered direct offering; insiders buy 2.36M shares at $0.55
2,363,636 shares sold to insiders (directors, officers, existing stockholders) at $0.55/share.
VolitionRx raises up to $1.9M in registered direct offering with warrants for additional $2.7M
Offering includes 445,648 Insider Shares at $0.5722 and 2,857,389 shares with warrants at $0.5722.
VolitionRx Q3 revenue $475K, up 187% YoY; sold >110K Nu.Q Vet tests in 9 months
Q3 2024 revenue $475K, up 187% YoY; YTD revenue $1M, up 96%.
VolitionRx appoints Timothy Still as Chairman, effective November 6, 2024
Timothy Still appointed non-executive Chairman and director of VolitionRx; board expanded to 8 members.
VolitionRx appoints Dr. Ethel Rubin as independent director; board expands to 7
Dr. Rubin appointed effective Sept 30, 2024; board increased from 6 to 7 members.
Employment agreement with Dr. Gaetan Michel as CEO of Belgian Volition, effective Sept 1, 2024, with €12,000/month salary plus 13th month bonus.
VolitionRx markets oncology portfolio for out-licensing via PharmaVentures
Company engaged PharmaVentures as licensing adviser; document made available to third parties starting September 16, 2024.
VolitionRx Q2 revenue up 83% to $396K; H1 test sales exceed full-year 2023
Q2 revenue $396K (+83% YoY); H1 revenue $567K (+55% YoY).
Gross proceeds of ~$7M from sale of 12.7M shares/pre-funded warrants at $0.55 each; warrants exercisable at $0.57.
VolitionRx shareholders approve 75% increase in authorized shares to 175M and new equity plan
Authorized shares increased from 100M to 175M (75% increase), effective July 2, 2024 via Certificate of Amendment.
VolitionRx mid-year: Vet test in 15 countries, $23M milestones, human license target H2 2024
Nu.Q Vet Cancer Test now available in 15 countries via Antech, IDEXX, Fujifilm; aiming to triple 2023 test sales of 58,000.
Q1 2024 revenue ~$170,000, up 15% YoY; cash and equivalents $11.8M as of March 31, 2024.
VolitionRx board shrinks from 8 to 6; two long-serving directors retire; quorum lowered to 33%
Executive Chairman Faulkes and director Futcher to retire after 12 & 7 years, not standing for re-election at July 2, 2024 meeting.
VolitionRx reports FY2023 revenue up 153% to $775K; cash $20.7M
Revenue of ~$775K in FY2023, up 153% YoY; net cash used in operations $18.1M.
VolitionRx appoints Dr. Andrew Retter as Chief Medical Officer effective April 1, 2024
Dr. Retter is an Intensive Care Consultant at Guy's and St. Thomas' NHS Foundation Trust, London, and dual-registered in Intensive Care and Haematology.
VolitionRx receives $13.0M milestone from Heska for Nu.Q Vet Cancer Test transfer
Received $13.0 million in milestone payments from Heska Corporation.
VolitionRx secures ~$5.5M financing from Belgian regional government WE
Total financing €5.0M (~$5.5M) from Wallonie Entreprendre; €2.5M unsecured loan at 8% interest, maturity Dec 2028.
VolitionRx reports 185% revenue increase in 9M 2023; FDA 510(k) pathway for NETs
Revenue for first nine months 2023 was $531k, up 185% YoY; Nu.Q Vet Cancer Test revenue grew ~5x.
Submitted Breakthrough Device Designation Request to FDA for Nu.Q technology in sepsis in June 2023.
VolitionRx stockholders approve 1.95M share increase in 2015 Stock Incentive Plan
Stockholders voted to amend the 2015 Stock Incentive Plan, increasing available shares by 1,950,000 to 9,700,000.
VolitionRx prices $16.5M public offering of 13M shares at $1.27 per share
Gross proceeds of $16.5M from 13M shares at $1.27/share; net proceeds ~$15.4M.
VolitionRx Q1 sales jump 381% to $124k; cash $10M; expects $13M milestones
Nu.Q Vet Cancer Test sales rose 381% YoY to $124,000 in Q1 2023.
VolitionRx FY22 revenue $300k, cash $10.9M; Heska deal advances with $10M upfront
Revenue $0.3M, up 240% YoY; net cash used in operations $15.3M ($1.3M/month).
VolitionRx raises $7.525M in public offering of 4.3M shares plus full over-allotment
Gross proceeds $7.525M from 4,300,000 shares at $1.75/share; net ~$8.0M after underwriting discount.
On May 12, 2026, Mickie Henshall notified the Board of Directors (the “Board”) of VolitionRx Limited (the “Company”) of her decision not to stand for re-election to the Board at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).
On September 30, 2024, the Board of Directors (the “ Board ”) of VolitionRx Limited (the “ Company ”), pursuant to the Company’s Bylaws, passed a resolution to increase the size of the Board to seven (7) members and appointed Dr. Ethel Rubin to fill the new vacancy on the Board effective as of September 30, 2024.
Dr. Faulkes will also step down as Executive Chairman, and Dr. Futcher will also step down as a member and Chair of the Board’s Nominations and Governance Committee and member of the Audit Committee, at the same time.
Assuming the re-election of the Board-nominated director nominees at the Annual Meeting, the Board has appointed Guy Innes as interim Chairman of the Board and as the Chair of the Nominations and Governance Committee, effective immediately upon such re-election, in addition to his continuing role as a member and Chair of the Audit Committee.
On April 24, 2024, Dr. Martin Faulkes and Dr. Edward Futcher each informed the Board of Directors (the “Board”) of VolitionRx Limited (the “Company”) of their intention to retire from the Board of the Company following the conclusion of the current director service year and to not stand for re-election at the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”), which is expected to be held on July 2, 2024.
On November 22, 2022, Dr. Jason Terrell tendered written notice to VolitionRx Limited (the “Company”) of his resignation as Chief Medical Officer of the Company, effective as of November 18, 2022.
On August 15, 2022, the Board of Directors (the “ Board ”) of VolitionRx Limited (the “ Company ”), pursuant to the Company’s Bylaws, passed a resolution to increase the size of the Board to nine (9) members and appointed Ms. Mickie Henshall to fill the new vacancy on the Board effective as of August 15, 2022.
Max materiality 0.80 · Median 0.60 · Most common event other_material